Avalo exchanges Series C shares to lift beneficial ownership cap; revises exec severance

Avalo Therapeutics, Inc.

Exchanged 4,294.675 Series C shares for new Series C-1 shares, removing restriction that capped beneficial ownership at 4.99% (now 9.99%).
After exchange, 4,085.379 Series C shares remain outstanding.
Amended employment agreements for CEO Neil, CFO Sullivan, CMO Doyle, and CBO Boyd, changing severance and change-in-control terms.
CEO Neil gets 18-month base salary severance (others 12 months); on change-in-control termination, 1.5x base + 1x target bonus (others 1x/1x).
Pre-amendment options vest fully on qualifying termination; exercise period extended to 12 months for CEO/CFO, 6 months for CMO/CBO.

item 3.02 item 3.03 item 5.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Avalo Therapeutics, Inc. issued 4,294.675 shares of preferred stock to an accredited investor.

Security: preferred stock
Shares: 4,294.675 shares
Purchaser: an accredited investor

Exact text from the filing

On June 11, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with an accredited investor to exchange 4,294.675 outstanding shares of the Company’s outstanding Series C non-voting convertible preferred stock, $0.001 par value per share (the “Series C Preferred Stock”) for 4,294.675 shares of the Company’s newly created Series C-1 non-voting convertible preferred stock, $0.001 par value per share (the “Series C-1 Preferred Stock”), such exchange, the “Exchange”.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Avalo Therapeutics, Inc.: Filed Certificate of Designation to designate Series C-1 Preferred Stock (effective 2026-06-11).

Change: charter amendment
Effective: 2026-06-11

Exact text from the filing

On June 11, 2026, in connection with the Exchange, the Company filed a Certificate of Designation to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Designation”), with the Secretary of State of the State of Delaware for the purpose of designating the Series C-1 Preferred Stock.

View on SEC.gov

226 equity issuances filed in the last 30 days. Browse all equity issuances →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001534120-26-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.